
March 2015
don't forget to update the issue and next review variables!!!
|
|
|
Changes in this release
|
Topic or section
|
Brief description
|
Reviewer
|
Prescription Charts
|
The following charts have been replaced under Chronic Lymphocytic Leukaemia:
- Rituximab/Cyclo/Fludarabine 375 IV
- Rituximab/Cyclo/Fludarabine 375 PO
- Rituximab/Cyclo/Fludarabine 500 IV
- Rituximab/Cyclo/Fludarabine 500 PO
The following charts have been replaced under Non Hodgkin Lymphoma:
- R-CVP
- R-CHOP
- R-FCM
- Fractionated R-ICE G
- Mantle cell Maxi-CHOP (replaces Maxi-CHOP Cycle 1, and Maxi-CHOP Cycle 3+)
- Mantle cell Maxi HDcytarabine (replaces Maxi-CHOP Rituximab and HD Cytarabine, and Maxi-CHOP Rituximab and HD Cytarabine Stem Cell Mobilisation)
- R-Hyper-CVAD
- R-MTX Ara-C
- CODOX-M - patients 65 years or less
- CODOX-M - patients over 65
- R IVAC - patients 65 years or less
- R IVAC - patients over 65
- Rituximab 375
- Ritux hyper-CVAD cycles 1 and 3
- Ritux MTX cytarabine cycles 2 and 4
The following new chart has been added to Non Hodgkin Lymphoma:
- R-CEOP
The following new charts have been added under Waldenstroms:
- Rituximab cladribine daily SC
- Rituximab fludarabine PO
|
Jenny Roberts
|
Myelodysplasia
|
Assessment of Prognosis was updated.
New information was added on:
|
Emma-Jane McDonald
|
Veno Occlusive Disease of the Liver
|
This sub-section was reviewed and updated.
|
Andrew Butler
|
Topic Code: 154602